In December 2022, President Joe Biden signed into law the Medical Marijuana and Cannabidiol Research Expansion Act-legislation that will make it easier for scientists and manufacturers to study the effects of marijuana and develop guidelines for use. Those hurdles include marijuana’s classification as a Schedule I substance, which requires researchers to earn approval from multiple federal agencies for studies.ĪPA has been advocating for reforms in cannabis research regulations to ensure that science is available to inform product policies, clinical decisions for therapeutic use, and public understanding about the health effects across the life span. “Science is having a hard time keeping up with the enormous increase in products available, especially because researchers have been hamstrung by regulatory hurdles,” said Columbia University’s Margaret Haney, PhD, a professor of neurobiology and director of the school’s Cannabis Research Laboratory. Among the popular offerings are cannabis concentrates with extremely high levels of tetrahydrocannabinol (THC), the main psychoactive compound in cannabis that produces the euphoric “high” sensation. Cannabis users have access to an unprecedented variety of purported antidotes for everything from anxiety to insomnia to posttraumatic stress disorder (PTSD)-claims that have yet to be validated by research. In 2021, more than 36 million people 12 and older reported using cannabis in the past month-double the number compared with a decade earlier, according to data from the Substance Abuse and Mental Health Services Administration’s National Survey of Drug Use and Health.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |